HTGMQ (HTG Molecular Diagnostics) Scaled Net Operating Assets: -0.12 (As of Mar. 2023)


HTGMQ HTG Molecular Diagnostics Inc HTGMQ
12 GF Score
Price $0.00
View Full Analysis

What is HTG Molecular Diagnostics Scaled Net Operating Assets?

HTG Molecular Diagnostics HTGMQ 12 Scaled Net Operating Assets is -0.12 as of Mar. 2023. GuruFocus rates HTGMQ with a GF Score™ of 12/100.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

HTG Molecular Diagnostics's operating assets for the quarter that ended in Mar. 2023 was $4.30 Mil. HTG Molecular Diagnostics's operating liabilities for the quarter that ended in Mar. 2023 was $6.41 Mil. HTG Molecular Diagnostics's Total Assets for the quarter that ended in Dec. 2022 was $17.78 Mil. Therefore, HTG Molecular Diagnostics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2023 was -0.12.

HTG Molecular Diagnostics Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for HTG Molecular Diagnostics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HTG Molecular Diagnostics Scaled Net Operating Assets Chart

HTG Molecular Diagnostics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 0.05 -0.04 0.01 -0.07

HTG Molecular Diagnostics Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 0.02 0.03 -0.15 -0.12

HTGMQ vs ABMC, TMO, DHR: Scaled Net Operating Assets Comparison

For the Diagnostics & Research subindustry, HTG Molecular Diagnostics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HTG Molecular Diagnostics Scaled Net Operating Assets vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, HTG Molecular Diagnostics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where HTG Molecular Diagnostics's Scaled Net Operating Assets falls into.


HTGMQ
12GF Score
HTG Molecular Diagnostics Inc HTGMQ
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HTG Molecular Diagnostics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

HTG Molecular Diagnostics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2022 )
=(Operating Assets (A: Dec. 2022 )-Operating Liabilities (A: Dec. 2022 ))/Total Assets (A: Dec. 2021 )
=(5.567-7.552)/30.461
=-0.07

where

Operating Assets(A: Dec. 2022 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=17.778 - 12.211
=5.567

Operating Liabilities(A: Dec. 2022 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=12.386 - 0.546 - 4.288
=7.552

HTG Molecular Diagnostics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2023 )
=(Operating Assets (Q: Mar. 2023 )-Operating Liabilities (Q: Mar. 2023 ))/Total Assets (Q: Dec. 2022 )
=(4.303-6.411)/17.778
=-0.12

where

Operating Assets(Q: Mar. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=10.866 - 6.563
=4.303

Operating Liabilities(Q: Mar. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=10.391 - 0.423 - 3.557
=6.411

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of -0.12 mean?
HTG Molecular Diagnostics (HTGMQ) has a Scaled Net Operating Assets of -0.12 as of Mar. 2023. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on HTG Molecular Diagnostics and its competitors.
Is HTG Molecular Diagnostics' Scaled Net Operating Assets too high?
HTG Molecular Diagnostics' current Scaled Net Operating Assets is -0.12. Overall, HTG Molecular Diagnostics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does HTG Molecular Diagnostics' Scaled Net Operating Assets compare to ABMC and TMO?
HTG Molecular Diagnostics' Scaled Net Operating Assets of -0.12 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Diagnostics & Research company?
A good Scaled Net Operating Assets depends on the Medical Diagnostics & Research industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on HTG Molecular Diagnostics and its competitors. HTG Molecular Diagnostics's current Scaled Net Operating Assets is -0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HTG Molecular Diagnostics stock overvalued right now?
HTG Molecular Diagnostics (HTGMQ) has a current Scaled Net Operating Assets of -0.12. The current Scaled Net Operating Assets is -0.12. HTG Molecular Diagnostics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For HTG Molecular Diagnostics (HTGMQ), the current Scaled Net Operating Assets is -0.12 as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HTG Molecular Diagnostics Business Description

Address 3430 E. Global Loop, Tucson, AZ, USA, 85706
HTG Molecular Diagnostics Inc is a life science company whose mission is to advance precision medicine through its transcriptome-wide profiling and medicinal chemistry technologies. The company derives revenue from sales of its HTG EdgeSeq system and integrated next-generation sequencing-based HTG EdgeSeq research use only assays and from sample processing services performed in its VERI/O laboratory. The company operates in one segment and its customers and distributors are located in the United States and Europe.
12GF Score

Get the complete analysis for HTGMQ

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price